A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel

By afschroeder • July 29, 2026

Shah M, DeBusk L, Bohman MH, Rosenberg A, Burshtein J, Zakria D, Armstrong A, Boh E, Gottlieb AB, Khattri S, Litchman G, Merola J, Murina A, Lebwohl M. A review of the indications, safety, and efficacy of deucravacitinib: An expert consensus panel. Dermatol Online J. 2026 May 8;32(2). doi: 10.25251/ymnfwz12. PMID: 42522479.

Tags: combination therapy, cutaneous lupus erythematosus, Dermatology, deucravacitinib, herpes zoster, laboratory monitoring, malignancy, psoriasis, psoriatic arthritis, Publications, systemic lupus erythematosus, Tuberculosis

Related Posts

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains

Zakria D, Shah M, Rosenberg A, Burshtein J, DeBusk L, Altman DA, Armstrong AW, Gottlieb AB, Han G, Khattri S, Shaigany S, Weinberg JM, Lebwohl[...]

Vitiligo in the United States: A 10-year study of patient characteristics, comorbidities, and treatment patterns

Huang MY, Smart K, Lee K, Kingston P, Yee D, Peterson H, Korouri E, Armstrong AW. Vitiligo in the United States: A 10-year study of[...]

The role of aryl hydrocarbon receptor agonists in the management of inflammatory skin diseases: An expert consensus panel

DeBusk L, Bartley B, Armstrong AW, Bunick CG, Del Rosso J, Desai SR, Eichenfield LF, Elewski BE, Golant AK, Issa N, Stein Gold L, Swanson[...]